Cytomed Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
CytoMed Therapeutics Limited, a clinical-stage biopharmaceutical company, reported increased losses in 2025 as it advances multiple cell-based immunotherapy product candidates through preclinical and Phase I clinical trials.
NASDAQ
CytoMed Therapeutics Limited announces its full year 2024 financial results, highlighting ongoing clinical trial advancements and a solid financial foundation for future growth.
NASDAQ
CytoMed Therapeutics Limited's 2023 annual report reveals ongoing R&D investments and strategic financial management amidst operating losses.